Drug intelligence / Profile preview

sertraline + alprazolam

Development stage
Unknown
Lead developer
Micro Labs
Modality
Small Molecules
Administration
Oral
01

Overview

Sertraline + alprazolam is a fixed-dose combination of two pharmaceutical agents used primarily in the treatment of panic disorder (with or without agoraphobia) and depression. Sertraline is a selective serotonin reuptake inhibitor (SSRI) that increases serotonin levels in the brain, thereby improving mood, cognition, and memory. Alprazolam is a benzodiazepine that enhances the activity of gamma-aminobutyric acid (GABA), producing anxiolytic, muscle relaxant, and sedative effects. The combination targets both depressive symptoms and anxiety/panic attacks by modulating serotonergic neurotransmission (sertraline) and potentiating inhibitory GABAergic signaling (alprazolam)[5][8]. This dual mechanism provides symptomatic relief for patients with comorbid anxiety and depressive disorders.

Brand names
Anxit PlusAlprax PlusAlprax ForteTrika ForteTrika PlusAnxit FortAlarm PlusUnitracCensir Forte
Other names
sertraline + alprazolam
02

Targets

SERT (Sodium-dependent serotonin transporter)GABRR (GABA-A receptor subunit rho)TMEM97 (Sigma-2 receptor complex (TMEM97/PGRMC1))DAT (Dopamine plasma membrane transport protein)SIGMAR1 (Sigma non-opioid intracellular receptor 1)NET (Norepinephrine Transporter)

Beyond the preview

Go deeper on sertraline + alprazolam.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on sertraline + alprazolam.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call